• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Armata Pharmaceuticals Inc.

    8/13/25 5:16:56 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARMP alert in real time by email
    S-8 1 tm2523056d1_s8.htm FORM S-8

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    ARMATA PHARMACEUTICALS, INC.

    (Exact name of registrant as specified in its charter)

     

    Washington 91-1549568

    (State or other jurisdiction of

    incorporation or organization) 

    (I.R.S. Employer

    Identification No.) 

     

    5005 McConnell Avenue

    Los Angeles, CA 90066

    (Address of Principal Executive Offices) (Zip Code)

     

    Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan

    Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan

     

    (Full titles of the plans)

     

    Armata Pharmaceuticals, Inc.

    5005 McConnell Avenue

    Los Angeles, CA 90066

    (Name and address of agent for service)

     

    (310) 655-2928

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Deborah L. Birx

    Armata Pharmaceuticals, Inc.

    5005 McConnell Avenue

    Los Angeles, CA 90066

    (310) 655-2928

    Jared Fertman

    Willkie Farr & Gallagher LLP

    787 Seventh Avenue

    New York, New York 10019-6099

    (212) 728-8000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
    Non-accelerated filer x    Smaller reporting company x
          Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE
    REGISTRATION OF ADDITIONAL SHARES
    PURSUANT TO GENERAL INSTRUCTION E

     

    Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 (this “Registration Statement”) is filed by Armata Pharmaceuticals, Inc. (the “Registrant”) to register an additional 1,811,295 shares of the Registrant’s common stock, par value $0.01 per share (“Common Stock”), issuable under the Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan (the “Armata 2016 Plan”) or the Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan (the “Armata 2016 ESPP”).  Such shares consist of the following:

     

    ·(i) 1,809,153 shares of Common Stock that were automatically added to the shares authorized for issuance under the Armata 2016 Plan on January 1, 2025, pursuant to an “evergreen” provision contained in the Armata 2016 Plan. Pursuant to such “evergreen” provision, on January 1st of each calendar year, from January 1, 2017 through and including January 1, 2026, the number of shares authorized for issuance under the Armata 2016 Plan is automatically increased by: (a) a number equal to 5% of the total number of shares of the Registrant’s capital stock outstanding on December 31st of the preceding calendar year, or (b) a lesser number of shares determined by the Registrant’s board of directors (the “Board”); and

     

    ·(ii) 2,142 shares of Common Stock that were automatically added to the shares authorized for issuance under the Armata 2016 ESPP on January 1, 2025, pursuant to an “evergreen” provision contained in the Armata 2016 ESPP. Pursuant to such provision, on January 1st of each calendar year, from January 1, 2017 through and including January 1, 2026, the number of shares authorized for issuance under the Armata 2016 ESPP is automatically increased by a number equal to the least of: (a) 1% of the total number of shares of the Registrant’s capital stock outstanding on December 31st of the preceding calendar year; (b) 2,142 shares; or (c) a number determined by the Board that is less than (a) and (b).

     

    This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statement on Form S-8 filed with the Commission on January 23, 2024 (File No. 333-276657), November 15, 2023 (File No. 333-275580), June 22, 2016 (File No. 333-212183), May 1, 2017 (File No. 333-217563), November 14, 2017 (File No. 333-221564), March 28, 2018 (File No. 333-223987), and June 10, 2019 (File No. 333-232058), respectively (the “Prior Registration Statements”), in each case, to the extent not superseded hereby. The additional shares of Common Stock being registered by this Registration Statement are of the same class as those securities registered on the Prior Registration Statements.

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    All information required by Part I to be contained in the prospectus is omitted from this Registration Statement in accordance with Section 428 of the Securities Act of 1933, as amended (the “Securities Act”) and the instructions to Form S-8 and instead will be delivered, pursuant to Rule 428 under the Securities Act, to each participant in the Armata 2016 Plan and the Armata 2016 ESPP, as applicable.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents By Reference

     

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plan are effective. Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

     

    - 2 -

     

     

    The following documents, which we have filed with the Securities and Exchange Commission (the “Commission”), are incorporated by reference in this registration statement:

     

    ·The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 20, 2025;

     

    ·The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025 filed with the Commission on May 14, 2025 and August 12, 2025;

     

    ·The Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 28, 2025 (as amended and supplemented);

     

    ·The Registrant’s Current Reports on Form 8-K, filed with the Commission on March 12, 2025, April 2, 2025, May 1, 2025, June 13, 2025 and August 12, 2025 (only with respect to information filed under items 1.01, 2.03 and 9.01); and

     

    ·The description of our common stock contained in our registration statement on Form 8-A, filed with the Commission on August 18, 2015, including all amendments and reports filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment that indicates that all shares of common stock offered hereby have been sold or which deregisters all shares of common stock then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this registration statement.

     

    Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this registration statement.

     

    - 3 -

     

     

    Item 8. Exhibits.

     

    The following exhibits are filed herewith:

     

    Exhibit    
    Number   Exhibit Description
    4.1   Amended and Restated Articles of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 16, 2015).
         
    4.2   Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K, filed with the SEC on April 24), 2017.
         
    4.3   Statement of Correction to Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2018).
         
    4.4   Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 18, 2018).
         
    4.5   Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 10, 2019).
         
    4.6   Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 11, 2019).
         
    4.7   Articles of Amendment to Articles of Incorporation of the Company (effective March 26, 2020) (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 30, 2020).
         
    4.8   Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.5 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).
         
    4.9   Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on December 11, 2019).
         
    4.10   Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on February 26, 2020).
         
    5.1   Opinion of Counsel
         
    23.1   Consent of Independent Registered Public Accounting Firm
         
    23.2   Consent of Counsel (included in Exhibit 5.1 to this Registration Stated and filed herewith)
         
    24.1   Power of Attorney (included on the signature pages of this Registration Statement)
         
    99.1   Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan, as amended incorporated by reference to Exhibit 99.1 to the registrant’s Registration Statement on Form S-8, filed with the SEC on June 10, 2019).
         
    99.2   Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.10 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).
         
    107   Filing Fee Table

     

    - 4 -

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on August 13, 2025.

     

      Armata Pharmaceuticals, Inc.
       
      By: /s/ Deborah L. Birx
        Deborah L. Birx
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints each of Deborah L. Birx and David D. House as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    SIGNATURE   TITLE   DATE
             
    /s/ Deborah L. Birx   Chief Executive Officer and Director   August 13, 2025
    Deborah L. Birx, M.D.   (Principal Executive Officer)    
             
    /s/ David D. House   Senior Vice President, Finance   August 13, 2025
    David D. House   (Principal Financial Officer)    
             
    /s/ Robin C. Kramer   Chair of the Board of Directors   August 13, 2025
    Robin C. Kramer        
             
    /s/ Jules Haimovitz   Director   August 13, 2025
    Jules Haimovitz        
             
    /s/ Odysseas D. Kostas   Director   August 13, 2025
    Odysseas D. Kostas, M.D.        
             
    /s/ Joseph M. Patti   Director   August 13, 2025
    Joseph M. Patti, Ph.D.        
             
    /s/ Todd C. Peterson   Director   August 13, 2025

    Todd C. Peterson, Ph.D.

           
             
    /s/ Sarah J. Schlesinger   Director   August 13, 2025

    Sarah J. Schlesinger, M.D.

           

     

    - 5 -

     

    Get the next $ARMP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARMP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ARMP
    SEC Filings

    View All

    SEC Form S-8 filed by Armata Pharmaceuticals Inc.

    S-8 - Armata Pharmaceuticals, Inc. (0000921114) (Filer)

    8/13/25 5:16:56 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Armata Pharmaceuticals Inc.

    S-3 - Armata Pharmaceuticals, Inc. (0000921114) (Filer)

    8/13/25 5:15:01 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Armata Pharmaceuticals Inc.

    10-Q - Armata Pharmaceuticals, Inc. (0000921114) (Filer)

    8/12/25 4:36:27 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Armata Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Armata Pharmaceuticals with a rating of Buy and set a new price target of $7.00 from $5.00 previously

    3/22/21 6:28:33 AM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Birx Deborah covered exercise/tax liability with 13,637 shares, decreasing direct ownership by 6% to 217,377 units (SEC Form 4)

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    7/14/25 4:05:21 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Birx Deborah covered exercise/tax liability with 28,986 shares, decreasing direct ownership by 11% to 231,014 units (SEC Form 4)

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    4/25/25 4:07:12 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Business Officer Kyme Pierre covered exercise/tax liability with 1,027 shares, decreasing direct ownership by 9% to 10,491 units (SEC Form 4)

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    4/25/25 4:06:15 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

    Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS ANGELES, Aug. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2025, and provided a corporate update.

    8/12/25 4:05:00 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

    All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy No treatment-related serious adverse events were observed with repetitive intravenous dosing LOS ANGELES, May 19, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced positive topline results from its Ph

    5/19/25 7:00:00 AM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

    LOS ANGELES, May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 and Recent Developments: Anticipating announcement of topline results from Phase 1b/2a diSArm study of intravenous AP-SA02 as

    5/14/25 4:05:00 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARMP
    Leadership Updates

    Live Leadership Updates

    View All

    Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

    LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16th. Armata's Corporate Controller, Richard Rychlik, will retain the position of Controller. "We are delighted to welcome David to the Armata t

    8/15/24 4:45:00 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

    LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2023, and provided a corporate update.   Second Quarter 2023 and Recent Developments: Announced leadership transition whereby world‐renowned healthcare leader and former Innoviva Board member Dr. Deborah L. Birx has been appointed Armata's new Chi

    8/14/23 7:00:00 AM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

    Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t

    7/11/23 8:00:00 AM ET
    $ARMP
    $INVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ARMP
    Financials

    Live finance-specific insights

    View All

    Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

    Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Announced positive topline Phase 3 zoliflodacin data for treatment of gonorrhea in November 2023 Repurchased $11.0 million of common stock Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select cor

    11/1/23 4:15:00 PM ET
    $ARMP
    $INVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

    Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the second quarter of 2023 Received FDA approval for XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Repurchased $9.2 million of common stock Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the second quarter ended June 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives

    8/2/23 4:05:00 PM ET
    $ARMP
    $INVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Innoviva Reports First Quarter 2022 Financial Results

    Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023. Invested $45.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP) ("Armata"), an anti-infectives leader. Made a non-binding offer to acquire and provided $15.0 million convertible debt financing to Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an anti-infectives leader. Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2022. Gross royalty revenue

    4/27/22 5:11:00 PM ET
    $ARMP
    $ETTX
    $INVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations